Metformin, thiazolidinediones, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT2 inhibitors may be useful for patients with NAFLD or NASH, but only thiazolidinediones may be able to attenuate fibrosis or even cirrhosis (Table 2). Here, SLC5A2 is linked to metabolic dysfunction-associated steatohepatitis.